Industry-Provided Assets

Assets in this table are alphabetized by mechanism of action. These compounds and biologics have undergone significant pre-clinical and safety testing in humans.

2019 Table of Assets 

Code Number & Link to More Information

Mechanism
of Action

Original Development Indication(s)

Route of Administration Formulation Available
(CNS Penetrant+)

AZD1656 (PDF - 114KB)

Glucokinase (GK) activator

Type 2 Diabetes

Oral
(No/Low CNS)

AZD2014 (PDF - 93KB)
Vistuserib

Dual mTORC1 and mTORC2 inhibitor

Oncology

Oral
(No/Low CNS)

AZD5213 (PDF - 114KB)

Histamine receptor 3 (H3) antagonist (inverse agonist)

Neuro

Oral
(CNS)

AZD5904 (PDF - 112KB)

Myeloperoxidase (MPO) inhibitor

Multiple sclerosis (MS), and Chronic obstructive pulmonary disease (COPD)

Oral
(No/Low CNS)

RDEA119
Refametinib (PDF - 73KB)

MEK1/2 inhibitor

Oncology

Oral
(Low CNS)

ZD4054 (PDF - 78KB)
zibotentan

Endothelin type A (ETA) antagonist

Oncology

Oral
(Low CNS)

PF-04995274 (PDF - 138KB)

5-Hydroxytryptamine 4 receptor (5-HT4) partial agonist

Gastroesophageal reflux disease

Alzheimer's disease

Oral
(Yes)

CE-224535 (PDF - 203KB)

Purinergic receptor 2 antagonist

Rheumatoid arthritis
Osteoarthritis

Oral

JNJ-18038683 (PDF - 67KB)

5-Hydroxytryptamine 7 receptor (5-HT7) antagonist

Major depressive disorder

Oral
(Yes)

JNJ-39269646 (PDF - 34KB)

Fast dissociating D2/D3/5-HT6 antagonist

Schizophrenia
Bipolar depression

Oral
(Yes)